Back to top
more

Atossa Genetics (ATOS)

(Delayed Data from NSDQ)

$4.43 USD

4.43
69,292

-0.04 (-0.89%)

Updated Feb 27, 2026 04:00 PM ET

After-Market: $4.37 -0.06 (-1.35%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.86%
2Buy18.17%
3Hold10.12%
4Sell5.62%
5Strong Sell2.90%
S&P50011.43%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (68 out of 243)

Industry: Medical - Instruments

Brokerage Reports

0 items in cart

Atossa Genetics Inc. [ATOS]

Reports for Purchase

Showing records 1 - 20 ( 76 total )

Company: Atossa Genetics Inc.

Industry: Medical - Instruments

Record: 1

12/15/2025

Company Report

Pages: 4

Z-Endox SABCS Roundup Across BC Treatment Lines

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 10.00

Research Provided by a Third Party

Company: Atossa Genetics Inc.

Industry: Medical - Instruments

Record: 2

12/04/2025

Company Report

Pages: 4

FDA Type C Meeting Complete; Z-endox to Advance Across Breast Cancer Treatment Paradigm

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 10.00

Research Provided by a Third Party

Company: Atossa Genetics Inc.

Industry: Medical - Instruments

Record: 3

11/12/2025

Company Report

Pages: 5

3Q25 Recap: Multiple Z-Endoxifen Regulatory Updates Expected in 4Q25

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 10.00

Research Provided by a Third Party

Company: Atossa Genetics Inc.

Industry: Medical - Instruments

Record: 4

10/07/2025

Company Report

Pages: 4

Phase 2 EVANGELINE Trial Streamlined to Optimize NDA-Enabling Activities in 2026

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 10.00

Research Provided by a Third Party

Company: Atossa Genetics Inc.

Industry: Medical - Instruments

Record: 5

09/09/2025

Company Report

Pages: 4

FDA Type C Meeting Requested for Z-endox in BC Risk Reduction; Takeaways From Our Fireside Chat

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 10.00

Research Provided by a Third Party

Company: Atossa Genetics Inc.

Industry: Medical - Instruments

Record: 6

08/12/2025

Company Report

Pages: 5

2Q25 Recap: Focus Remains on 4Q25 IND Filing in Metastatic ER+/HER2- Breast Cancer

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 10.00

Research Provided by a Third Party

Company: Atossa Genetics Inc.

Industry: Medical - Instruments

Record: 7

07/29/2025

Company Report

Pages: 4

Positive FDA Feedback Generates Path to Z-Endoxifen Phase 2/3 IND Submission in 4Q25

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 10.00

Research Provided by a Third Party

Company: Atossa Genetics Inc.

Industry: Medical - Instruments

Record: 8

05/13/2025

Company Report

Pages: 5

1Q25 Recap: Plans for Z-Endoxifen Development in Metastatic Breast Cancer to Come in 2025

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 10.00

Research Provided by a Third Party

Company: Atossa Genetics Inc.

Industry: Medical - Instruments

Record: 9

03/25/2025

Company Report

Pages: 5

4Q24 Recap: Strategic Prioritization of Metastatic Breast Cancer; EVANGELINE Updates Anticipated 2025

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 10.00

Research Provided by a Third Party

Company: Atossa Genetics Inc.

Industry: Medical - Instruments

Record: 10

03/12/2025

Company Report

Pages: 4

Metastatic Breast Cancer Chosen for Next Z-Endoxifen Indication; We Expect More Detail in 2025

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 10.00

Research Provided by a Third Party

Company: Atossa Genetics Inc.

Industry: Medical - Instruments

Record: 11

01/30/2025

Company Report

Pages: 5

The Patent Situation Explained; No Impact to Current Formulation/Trials

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 10.00

Research Provided by a Third Party

Company: Atossa Genetics Inc.

Industry: Medical - Instruments

Record: 12

12/12/2024

Company Report

Pages: 6

Data Readouts From EVANGELINE and KARISMA Studies Highlighted at SABCS

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 25.00

Research Provided by a Third Party

Company: Atossa Genetics Inc.

Industry: Medical - Instruments

Record: 13

11/13/2024

Company Report

Pages: 6

3Q24 Recap: KARISMA-Endoxifen and 80 mg PK Data Expected at SABCS in Dec

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 25.00

Research Provided by a Third Party

Company: Atossa Genetics Inc.

Industry: Medical - Instruments

Record: 14

11/04/2024

Company Report

Pages: 4

Z-endoxifen Demonstrates Improved Breast Density Reduction Compared to Tamoxifen

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Atossa Genetics Inc.

Industry: Medical - Instruments

Record: 15

10/31/2024

Company Report

Pages: 4

Initial I-SPY 2 Data Reinforce EVANGELINE Data to Date Despite Lower Dose

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 10.00

Research Provided by a Third Party

Company: Atossa Genetics Inc.

Industry: Medical - Instruments

Record: 16

08/12/2024

Company Report

Pages: 5

2Q24 Recap: Phase 2 Karisma Topline Data and I-SPY 2 Data on Track for 2H24

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 10.00

Research Provided by a Third Party

Company: Atossa Genetics Inc.

Industry: Medical - Instruments

Record: 17

06/28/2024

Company Report

Pages: 4

Z-endoxifen + Abemaciclib Study Protocol Changed to Increase Enrollment and Dose

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 10.00

Research Provided by a Third Party

Company: Atossa Genetics Inc.

Industry: Medical - Instruments

Record: 18

05/13/2024

Company Report

Pages: 6

1Q24 Recap: I-SPY 2 Data Expected in 2H24; EVANGELINE Study Enrollment Continues

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 25.00

Research Provided by a Third Party

Company: Atossa Genetics Inc.

Industry: Medical - Instruments

Record: 19

04/15/2024

Company Report

Pages: 4

I-SPY 2 Trial to Add a Z-endoxifen + Abemaciclib Arm for Treatment of Neoadjuvant Breast Cancer

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 10.00

Research Provided by a Third Party

Company: Atossa Genetics Inc.

Industry: Medical - Instruments

Record: 20

04/10/2024

Company Report

Pages: 5

EVANGELINE Data From 40 mg Z-Endoxifen Dose Increase Our Confidence in 80 mg Dose

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 10.00

Research Provided by a Third Party